Another FTSE 100 dividend stock I’d buy with my last £1k

Royston Wild discusses another FTSE 100 (INDEXFTSE: UKX) hero that could make you richer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In recent days I’ve taken the time to look at GlaxoSmithKline. I’ve explained that because of the growing investment in healthcare and medicines we’re seeing across the globe, and this FTSE 100 stock’s brilliant drugs pipeline, it’s a company I’d be happy to use my last few pounds to invest in.

But if I was shopping for stocks and only had £1,000, I’d also be drawn to Reckitt Benckiser Group (LSE: RB), another Footsie firm I believe is nailed-on to deliver brilliant shareholder returns in the years ahead.

Growth giant

The household goods giant has already more than proved it has what it takes to improve annual profits year after year and, consequently over the past half a decade alone, the bottom line has swelled by a sturdy-if-unspectacular 26%.

Many growth investors will no doubt be turning their noses up at this though, not to mention City predictions that Reckitt’s earnings will swell an extra 2% and 6% in 2019 and 2020, respectively. Of course, there’s plenty of shares out there with better profit growth projections over the next couple of years, although I doubt many will have the defensive strengths of this Footsie firm that all-but-guarantees exceptional returns over the long term.

I’ve long lauded Reckitt’s broad territorial footprint and its commitment to investing in its jammed portfolio of brands, including Gaviscon indigestion reliever and Durex contraceptives, providing the base for relentless profits expansion regardless of broader pressures on consumer spending power.  And the broad scope of Reckitt’s consumer healthcare labels is something that’s particularly exciting, not just because of the allure of their labels for customers.

In great health

Public consciousness of living a healthy lifestyle with a nutritious diet is driving demand for over-the-counter products like never before, and this isn’t just a phenomenon in developed economies. Indeed, increasing spending power in emerging regions is driving demand for consumer health goods too, territories in which Reckitt already has a sizeable stake.

Like-for-like sales at its consumer healthcare brands surged 4% in the most recent quarter, meaning that more than 60% of group revenues come from these labels. But Reckitt isn’t satisfied and expects much, much more.

As well as setting up a separate ‘Health Business Unit’ division under its RB 2.0 restructuring programme in early 2018, incorporating its health products as well as its then-newly-acquired Mead Johnson business and some of its Hygiene Home brands, it’s also cut the ribbon on its gigantic £105m healthcare development centre in Hull. The move represents the biggest single investment in Reckitt’s history and underlines the confidence it has in the potential size of this market, not to mention the company’s ambition to become the global leader in this field.

There’s a lot to like about this consumer goods colossus, in my opinion, thanks to its great growth profile and its long-running, progressive dividend policy (which throw up large yields of 2.9% and 3.1% for 2019 and 2020, respectively). It’s a Footsie share I’d happily buy today and cling onto for years to come.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: these FTSE 100 stocks could be among 2025’s big winners

Picking the coming year's FTSE 100 winners isn't an easy task, but we're all thinking about it at this time…

Read more »

Investing Articles

This UK dividend share is currently yielding 8.1%!

Our writer’s been looking at a FTSE 250 dividend share that -- due to its impressive 8%+ yield -- is…

Read more »

Investing Articles

If an investor put £10,000 in Aviva shares, how much income would they get?

Aviva shares have had a solid run, and the FTSE 100 insurer has paid investors bags of dividends too. How…

Read more »

Investing Articles

Here’s why I’m still holding out for a Rolls-Royce share price dip

The Rolls-Royce share price shows no sign of falling yet, but I'm still hoping it's one I can buy on…

Read more »

Investing Articles

Greggs shares became 23% cheaper this week! Is it time for me to take advantage?

On the day the baker released its latest trading update, the price of Greggs shares tanked 15.8%. But could this…

Read more »

Investing Articles

Down 33% in 2024 — can the UK’s 2 worst blue-chips smash the stock market this year?

Harvey Jones takes a look at the two worst-performing shares on the FTSE 100 over the last 12 months. Could…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Are National Grid shares all they’re cracked up to be?

Investors seem to love National Grid shares but Harvey Jones wonders if they’re making a clear-headed assessment of the risks…

Read more »

Investing For Beginners

Here’s what the crazy moves in the bond market could mean for UK shares

Jon Smith explains what rising UK Government bond yields signify for investors and talks about what could happen for UK…

Read more »